经直肠超声引导下经会阴125I粒子永久植入治疗前列腺癌的初步经验

目的探讨经直肠超声引导下经会阴125I粒子永久植入治疗前列腺癌的疗效和并发症。方法本组前列腺癌患者5例。年龄61￣83岁,平均70.4岁。临床分期T2bN0M0者2例,T3aN0M0者3例。Gleason评分6分者2例,7分者1例,8分者2例。术前前列腺特异性抗原(PSA)4.5￣17.5ng/ml。T3a期患者植入治疗前先行内分泌治疗。术前制定治疗计划,经直肠超声引导下经会阴125I粒子永久植入操作。术后观察PSA水平变化,连续3次PSA升高即为生化复发,观察术后尿路和直肠并发症发生情况。结果5例患者均术后恢复顺利。术后随访18个月,PSA均明显下降,PSA为0.1ng/ml者3例,0.01ng/ml者1例,0.04ng/m1者1例。5例患者术后均出现不同程度的尿路刺激症状,但6个月后逐渐好转。4例术后出现排便次数增多,术后3个月均好转。未发现尿失禁、直肠溃疡等并发症。结论经直肠超声引导下经会阴125I粒子永久植入治疗前列腺癌的疗效确切,创伤较小。     

重氮乳胶反向凝集试验与乳凝试验在血吸虫病临床诊断中的应用研究

本文应用日本血吸虫虫卵单克隆抗体及虫卵可溶性抗原，分别致敏新型免疫微球载体重氮基聚苯乙烯乳胶，制备出血吸虫反向乳凝试剂与乳凝试剂，并用于检测血吸虫病患者血清标本中的相应抗原和相应抗体，以此试验检测１９７份急慢性血吸虫病患者血清标本。结果反向乳凝试剂检出率为９０．４％，乳凝试剂检出率为９５．２％，均高于反向间接血凝法的８５．０％。反向乳凝试验与乳凝试验联合应用，既可早期诊断，又可判断疗效。试验采用玻片凝集法，３ｍｉｎ内即出结果，方法敏感．特异、简便和快速。     

Inhibitory effect of glycyrrhiza uralensis fish and chelidonium majus L on gastrocarcinogenesis induced by N-methyl-N′-nitron-N-nitrosoguanidine

In order to investigate the antagonistic effect of Glycyrrhiza Uralensis Fish (GUF) and Chelidonium maJus L (CML) on gastrccarcinogenesis induced by MNNG in Wastar rats, we treated the rats with MNNG alone (group 1) and with MNNG plus GUF and CML (group 2 and 3) respectively. The incidence of infiltrating adenocarcinoma of the glandular stomach and duodenum in group 2 was significantly lower than that in group 1 (26.7% vs. 67.8%). The differentiation and aggressivenees of carcinomas occured in group 2 were much better and mild than those in group 1. Present study also demonstrated that the inhibitory effect of CML on proliferation of human stomach carcinoma cell line MGC-803 was very remarkable; in addition, GUF and CML were able to antagonise the mutagenic activation of MNNG. These results suggest that GUF and CML may be empoyed in prevention of gastric carcinoma.     

Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer

Summary Thirty-one patients with stage IIIB or IV non-small cell lung cancer (NSCLC) were treated with intravenous 10-EdAM on a weekly basis. The starting dose was 80 mg/m², with subsequent doses adjusted depending on evidence of toxicity. There were 20 men and 11 women with a median age of 58 years (range, 33–75). Response was evaluated in 30 patients, 5 with evaluable but not measurable tumors and 25 with measurable indicator lesions. There were no complete remissions; 3 patients achieved partial remission. Nine patients had a minor response, 6 showed no change, and 12 had progressive disease. Median survival for all 31 patients was 43 weeks (range, 12–65+). During the first 3-week period, the 10-EdAM dose was reduced or withheld in 19 patients (because of stomatitis in 12, SGPT elevation in 3, skin rash in 2, and granulocytopenia in 2), escalated in 11 patients, and unchanged in 1 patient. A mean of 34–88 mg/m²of 10-EdAM (median, 50) was given per week during the first 5-week period. Myelotoxicity was infrequent and there was no significant nephrotoxicity. Considering the modest side effects of this treatment and the conservative dose-modification schedule which mandated substantial dose reductions, we conclude that 10-EdAM is a promising antitumor agent for NSCLC.     

A study on plasma norepinephrine and epinephrine levels in TCM liver syndromes.

The levels of plasma norepinephrine (NE) and epinephrine (E) were determined by HPLC in 220 patients with various TCM liver syndromes, and in 96 healthy subjects as controls. The plasma NE and E contents were higher in patients with liver excess syndromes, including Ganqi Yujie (GQYJ [symbol: see text]) syndrome, Ganyang Shangkang (GYSK [symbol: see text]) syndrome, Ganhuo Shangyan (GHSY [symbol: see text]) syndrome, and Ganyang Huafeng (GYHF [symbol: see text]) syndrome; while they were lower in patients with liver deficiency syndromes, including Ganqixu (GQX [symbol: see text]) syndrome, Ganxuexu (GXX [symbol: see text]) syndrome, and Ganyinxu (GYX [symbol: see text]) syndrome. Futhermore, when Ganshen Yinxu (GSYX [symbol: see text]) syndrome was turned into GYSK and then into GYHF, the plasma NE and E contents increased in order of precedence; while when GQYJ was turned into Ganyu Pixu (GYPX [symbol: see text]) syndrome, both NE and E contents decreased. The results suggest that the plasma NE and E contents are reliable objective parameters for the study of pathophysiological basis of the liver excess and liver deficiency syndromes, and the liver-kidney and liver-spleen interrelated syndromes.     

不同膳食特点地区中老年人血红蛋白及其与膳食营养的关系

测定分析不同膳食特点地区975例年龄45～74岁中老年人的血红蛋白及其与膳食营养素的关系。结果牧民及城市居民贫血率低，北京及新疆托里分别为7.6％和4.6％。男性比女性血红蛋白高，血红蛋白随年龄增加而降低。相关分析结果血红蛋白与膳食热能、蛋白质、动物蛋白质与总蛋白质比值呈显著正相关。结果说明血红蛋白可用于中老年人营养状态监测。     

环氧化酶-2基因启动子甲基化及表达与胃黏膜病变的关系

目的 探讨环氧化酶2(COX-2)基因启动子区甲基化水平和蛋白表达与胃黏膜病变的关系,并对其相关的影响因素进行研究.方法 以1201例患有不同胃黏膜病变的高危人群为研究对象,采用免疫组织化学方法榆测COX-2表达,用亚硫酸氢钠-变性高效液相色谱(DHPLC)对COX-2启动子甲基化率进行定量分析,采用13C尿素呼气实验(13C-UBT)对幽门螺旋杆菌(H priori)感染状况进行测定.结果 COX-2甲基化率中位数随胃黏膜病变的加重逐渐升高,在浅表性胃炎和慢性萎缩性胃炎(SG/CAG)、肠上皮化生(IM)及不确定性异型增生和异璎增生(Ind DYS/DYS)病变中分别为10.6%、11.8%、13.8%,各病变组之间差异有统计学意义(X2=8.312,P=0.016).分层分析显示,在H pylori感染阴性病例中,COX-2甲基化率仍随病变加重明显升高,在SG/CAG、IM、Ind DYS/DYS病变中其中位数分别为8.8%、10.6%、14.1%(X2=6.629,P=0.036).进一步分析发现,COX-2甲基化率随着COX-2表达强度的增强而降低,由COX-2弱阳性表达的13.3%降至强阳性表达的7.6%(X2=10.400,P=0.015).结论 COX-2启动子甲基化水平与胃黏膜病变程度及H pylori感染状况密切相关,并与COX-2表达强度呈负相关,说明COX-2启动子区异常甲基化可能在胃黏膜病变的演变过程中起重要作用.     

诺迪康对心脏活动的药理学作用

目的 :探讨诺迪康对心脏活动的药理学作用。方法 :运用 ms2 0 0 0多媒体生物信号处理系统 ,经 Straub法制备离体蛙心灌流标本并检测心脏活动 ,利用血流动力学方法检测家兔的心室活动等相关指标。结果 :2 0 9mg/L 诺迪康组的心肌收缩力增强 4 0 .38% (n =2 1,P <0 .0 0 1) ,4 18mg/L 诺迪康组的心肌收缩力增强 76 .4 4 % (n =17,P <0 .0 5 ) ,6 2 7mg/L 诺迪康组的心肌收缩力增强 10 4 .95 % (n =2 5 ,P <0 .0 1) ,对照组的心肌收缩力无明显变化 (n =2 5 ,P >0 .5 ) ;三个实验组及对照组对离体蛙心率均无作用 ,P >0 .0 5 ;家兔血流动力学方面 ,诺迪康组的 dp/dtmax增加了 2 1.0 8% (n =10 ,P <0 .0 5 ) ,其他各指标在对照组及诺迪康组均未见显著变化。结论 :诺迪康能增强心肌收缩力且有明显的剂量效应关系 ,可加速心肌的收缩速度但对心肌舒张无明显影响